Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Nivolumab (anti-PD-1 antibody) and atezolizumab (anti-PD-L1 antibody) have shown superior survival outcomes and improved adverse effects compared to standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. However, the efficacy of both treatments has not been directly compared...

Full description

Bibliographic Details
Main Authors: Miriam Alonso-García, Amparo Sánchez-Gastaldo, Miguel A. Muñoz-Fuentes, Sonia Molina-Pinelo, Laura Boyero, Johana Cristina Benedetti, Reyes Bernabé-Caro
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Pharmaceuticals
Subjects:
atezolizumab
immune checkpoint inhibitors (ICIs)
immunotherapy
nivolumab
non-small cell lung cancer (NSCLC)
real-world data
Online Access:https://www.mdpi.com/1424-8247/15/5/533

Internet

https://www.mdpi.com/1424-8247/15/5/533

Similar Items